NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results

Rhea-AI Summary

NovaBay Pharmaceuticals released its financial results for Q3 2024, highlighting a 14% increase in online Avenova sales and a 25% reduction in sales and marketing expenses. Total net sales for the quarter were $2.4 million, primarily from eyecare products. The gross margin was 65%, down from 67% in Q3 2023. Sales and marketing expenses decreased to $0.9 million, while general and administrative expenses increased to $1.7 million due to higher legal costs. The company reported a net loss of $2.2 million, or $0.60 per share, compared to a net loss of $1.8 million, or $13.11 per share, in Q3 2023.

For the first nine months of 2024, total net sales were $7.5 million, down from $8.4 million in the same period of 2023. The gross margin improved to 67% from 60%. Sales and marketing expenses decreased by 18%, while G&A expenses increased by 28%. The net loss for the nine months was $7.4 million, or $3.97 per share, compared to $7.5 million, or $79.58 per share, in the same period of 2023. The company had $0.8 million in cash and cash equivalents as of September 30, 2024, compared to $2.9 million as of December 31, 2023.

Positive

• 14% increase in online Avenova sales for Q3 2024.
• 25% reduction in sales and marketing expenses for Q3 2024.
• Gross margin improved to 67% for the first nine months of 2024.

Negative

• Total net sales decreased to $2.4 million for Q3 2024 compared to $2.5 million in Q3 2023.
• General and administrative expenses increased to $1.7 million in Q3 2024.
• Net loss increased to $2.2 million for Q3 2024 compared to $1.8 million in Q3 2023.
• Total net sales for the first nine months of 2024 decreased to $7.5 million from $8.4 million in the same period of 2023.
• Cash and cash equivalents decreased to $0.8 million as of September 30, 2024, from $2.9 million as of December 31, 2023.

Insights

Financial Analyst

NovaBay's Q3 results reveal a mixed performance with concerning underlying financials despite some positive operational metrics. The company's online Avenova sales grew 14% for the quarter and 19% year-to-date, demonstrating traction in their digital channel strategy. Management has simultaneously reduced sales and marketing expenses by 25%, indicating improved marketing efficiency.

However, overall quarterly sales remained essentially flat at $2.4 million compared to the prior year, while gross margins declined from 67% to 65%. More concerning is the widening net loss of $2.2 million ($0.60 per share) versus $1.8 million in Q3 2023, primarily driven by a significant 55% increase in G&A expenses to $1.7 million.

The company's cash position has deteriorated substantially to just $0.8 million, down from $2.9 million at year-end 2023. NovaBay's July 2024 public offering raised $3.9 million, suggesting cash burn concerns prompted the capital raise.

The divestiture of DERMAdoctor in March 2024 represents a strategic narrowing to focus on their eyecare portfolio, which now constitutes essentially all sales. While the company cites continued momentum and a successful Prime Day event in October, these positive indicators are overshadowed by the fundamental financial challenges of increasing losses and administrative costs that aren't translating to top-line growth.

• Online Avenova^® sales increase 14% for the quarter and 19% for the nine months
• Sales and marketing expenses declined 25% for the quarter and 18% for the nine months reflecting digital marketing optimization

EMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBay^® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2024.

“Avenova sales through the online channel for the quarter increased 14% over the prior year, while we reduced our marketing spend by 25% in the same period as we further optimized our highly efficient digital marketing programs,” said Justin Hall, CEO of NovaBay. “We saw continued momentum in Avenova online sales into the current quarter. Sales through Amazon in October continued to be strong with a successful Prime Day event.”

Financial results for the three and nine months ended September 30, 2024 and 2023 do not include results from DERMAdoctor, which was divested on March 25, 2024 and is accounted for in discontinued operations. Financial information about discontinued operations is available under “Divestiture and Discontinued Operations” in the Company’s Quarterly Report on Form 10-Q for the three months ended September 30, 2024, which will be filed with the Securities and Exchange Commission (the “SEC”) later today.

Third Quarter Financial Results

Total sales, net for the third quarter of 2024 were $2.4 million. Essentially all net sales for the quarter were derived from sales of eyecare products. Total sales, net for the third quarter of 2023 were $2.5 million, which included $2.4 million from sales of eyecare products and $0.1 million from sales of wound care products.

Gross margin on net sales for the third quarter of 2024 was 65%, compared with 67% for the third quarter of 2023, with the change primarily due to changes in the product mix.

Sales and marketing expenses for the third quarter of 2024 were $0.9 million, a 25% decrease from $1.3 million for the prior-year period, reflecting continued efficiencies in digital advertising and lower consulting costs. General and administrative (G&A) expenses for the third quarter of 2024 were $1.7 million, compared with $1.1 million for the third quarter of 2023, with the increase due to higher legal costs.

Accretion of interest and amortization of discounts on convertible notes for the third quarter of 2024 was $0.1 million, compared with $0.7 million for the third quarter of 2023.

Net loss attributable to common stockholders for the third quarter of 2024 was $2.2 million, or $0.60 per share. This compares with a net loss attributable to common stockholders for the third quarter of 2023 of $1.8 million, or $13.11 per share.

Nine Month Financial Results

Total sales, net for the nine months ended September 30, 2024 were $7.5 million, compared with $8.4 million for the nine months ended September 30, 2023.

Gross margin on net sales for the first nine months of 2024 was 67%, compared with 60% for the first nine months of 2023.

For the nine months ended September 30, 2024, sales and marketing expenses decreased 18% and G&A expenses increased 28%, both compared with the nine months ended September 30, 2023.

Net loss attributable to common stockholders for the first nine months of 2024 was $7.4 million, or $3.97 per share, compared with a net loss attributable to common stockholders for the first nine months of 2023 of $7.5 million, or $79.58 per share.

NovaBay had cash and cash equivalents of $0.8 million as of September 30, 2024, compared with $2.9 million as of December 31, 2023. In July 2024, the Company completed an underwritten public offering raising gross proceeds of $3.9 million.

About NovaBay Pharmaceuticals, Inc.

NovaBay's leading product Avenova^® Lid & Lash Cleansing Spray is often recommended by eyecare professionals for blepharitis and dry eye disease. Manufactured in the U.S., Avenova spray is formulated with NovaBay's patented, proprietary, stable and pure form of hypochlorous acid. All Avenova products are available directly to consumers through online distribution channels such as Amazon.com and Avenova.com.

Forward-Looking Statements

This release contains information about management's view of the Company's future expectations, plans and prospects that constitute forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the fact that they do not relate strictly to historic or current facts. Such forward-looking statements are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding our business strategies, including pursuing an asset sale of our Avenova business and a potential dissolution and liquidation of the Company, the expected timing of, our ability to complete, and the financial and business impact and effect of, such asset sale and/or such dissolution and liquidation, including with respect to distributions in connection with the dissolution and liquidation, and the impact and outlook for the Company’s Avenova products and business, as well as generally the Company’s expected future financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by these forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to the Company’s ability to, and the time it may take to, obtain stockholder approval of the asset sale and plan of dissolution, the Company’s ability to continue as a going concern while the asset sale and dissolution/liquidation are in process and other factors not within our control that may make the completion of the asset sale impossible or more difficult. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in the Company’s latest Form 10-K/Q filings and registration statements, as may be amended from time to time, and are further described in the definitive proxy statement that the Company filed with the SEC on October 16, 2024 (as may be supplemented), especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and the Company disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

Socialize and Stay Informed on NovaBay’s Progress
Like us on Facebook
Follow us on X
Connect with NovaBay on LinkedIn
Visit NovaBay’s Website

Avenova Purchasing Information
For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com
Avenova.com

Financial tables follow

NOVABAY PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except par value amounts)
		September 30, 2024				December 31, 2023
		(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents		$	776			$	2,924
Accounts receivable, net of allowance for credit losses ($3 at September 30, 2024 and December 31, 2023)			704				680
Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($126 and $264 at September 30, 2024 and December 31, 2023, respectively)			473				564
Prepaid expenses and other current assets			326				256
Current assets, discontinued operations			—				2,730
Total current assets			2,279				7,154
Operating lease right-of-use assets			1,042				1,296
Property and equipment, net			61				87
Other assets			495				478
Other assets, discontinued operations			—				19
TOTAL ASSETS		$	3,877			$	9,034
LIABILITIES AND STOCKHOLDERS’ EQUITY
Liabilities:
Current liabilities:
Accounts payable		$	396			$	906
Accrued liabilities			1,147				1,169
Secured Convertible Notes, net of discounts			—				1,137
Unsecured Convertible Notes, net of discounts			51				—
Operating lease liabilities			390				368
Current liabilities, discontinued operations			—				698
Total current liabilities			1,984				4,278
Warrant liabilities			—				334
Operating lease liabilities-non-current			821				1,108
Total liabilities			2,805				5,720
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.01 par value; 5,000 shares authorized;
Series B Preferred Stock; 1 and 6 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively			6				275
Series C Preferred Stock; 0 and 1 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively			—				1,675
Common stock, $0.01 par value; 150,000 shares authorized, 4,885 and 321 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively*			49				3
Additional paid-in capital*			183,262				176,210
Accumulated deficit			(182,245	)			(174,849	)
Total stockholders’ equity			1,072				3,314
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY		$	3,877			$	9,034

*	After giving retroactive effect to a 1-for-35 Reverse Stock Split that became effective May 30, 2024.

NOVABAY PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(in thousands, except per share data)
		Three Months Ended September 30,								Nine Months Ended September 30,
		2024				2023				2024				2023
Sales:
Product revenue, net		$	2,424			$	2,471			$	7,435			$	8,326
Other revenue, net			17				10				37				28
Total sales, net			2,441				2,481				7,472				8,354
Cost of goods sold			848				819				2,493				3,353
Gross profit			1,593				1,662				4,979				5,001
Operating expenses:
Research and development			4				4				32				36
Sales and marketing			947				1,263				3,021				3,674
General and administrative			1,703				1,093				5,611				4,385
Loss on divestiture of subsidiary			—				—				865				—
Total operating expenses			2,654				2,360				9,529				8,095
Operating loss			(1,061	)			(698	)			(4,550	)			(3,094	)
Non-cash gain on changes in fair value of warrant liabilities			—				—				114				216
Non-cash (loss) gain on change in fair value of embedded derivative liability			—				—				(18	)			40
Accretion of interest and amortization of discounts on convertible notes			(138	)			(655	)			(871	)			(1,156	)
Extinguishment of Secured Convertible Notes			(13	)			—				(13	)			—
Other expense, net			—				—				(549	)			(432	)
Net loss from continuing operations			(1,212	)			(1,353	)			(5,887	)			(4,426	)
Net loss from discontinued operations			—				(404	)			(124	)			(1,106	)
Net loss			(1,212	)			(1,757	)			(6,011	)			(5,532	)
Less: Increase to accumulated deficit due to adjustment to common stock warrant exercise price			(1,005	)			—				(1,005	)			—
Less: Increase to accumulated deficit due to adjustment to Preferred Stock conversion price			—				—				(380	)			(1,996	)
Net loss attributable to common stockholders		$	(2,217	)		$	(1,757	)		$	(7,396	)		$	(7,528	)
Basic and diluted net loss per share
Net loss per share from continuing operations*		$	(0.60	)		$	(10.10	)		$	(3.90	)		$	(67.89	)
Net loss per share from discontinued operations*			—				(3.01	)			(0.07	)			(11.69	)
Net loss per share attributable to common stockholders (basic and diluted)*		$	(0.60	)		$	(13.11	)		$	(3.97	)		$	(79.58	)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock (basic and diluted)*			3,710				134				1,863				95

*	After giving retroactive effect to a 1-for-35 Reverse Stock Split that became effective May 30, 2024.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20241107763026/en/

NovaBay Contact

Justin Hall

Chief Executive Officer and General Counsel

510-899-8800

jhall@novabay.com

Investor Contact

Alliance Advisors IR

Jody Cain

310-691-7100

jcain@allianceadvisors.com

Source: NovaBay Pharmaceuticals, Inc.

FAQ

What were NovaBay Pharmaceuticals' Q3 2024 financial results?

NovaBay Pharmaceuticals reported a net loss of $2.2 million, or $0.60 per share, with total net sales of $2.4 million, primarily from eyecare products.

How much did online Avenova sales increase in Q3 2024?

Online Avenova sales increased by 14% in Q3 2024.

What was the gross margin for NovaBay in Q3 2024?

The gross margin for NovaBay in Q3 2024 was 65%, down from 67% in Q3 2023.

How much did NovaBay reduce its sales and marketing expenses in Q3 2024?

NovaBay reduced its sales and marketing expenses by 25% in Q3 2024.

What was NovaBay's cash position as of September 30, 2024?

NovaBay had $0.8 million in cash and cash equivalents as of September 30, 2024.